Treatment of a syngeneic GB mouse model (CT-2A) with ITI-1001 resulted in increased antigen presentation, multi-antigen-specific CD4 and CD8 T cell responses, and around 56% long-term survival in tumor-bearing mice (99). The gene discussed is CD8A; the disease is neoplasm.